- Home
- PUMP vs GERN Comparison
PUMP vs GERN Comparison
Compare PUMP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PUMP | GERN |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | PUMP | GERN |
|---|---|---|
| Price | $12.11 | $1.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $12.29 | $2.90 |
| AVG Volume (30 Days) | 3.2M | ★ 16.9M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.76 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,269,158,000.00 | N/A |
| Revenue This Year | $0.93 | $32.27 |
| Revenue Next Year | $13.04 | $60.16 |
| P/E Ratio | $1,189.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.51 | $1.04 |
| 52 Week High | $13.25 | $2.01 |
Technical Indicators
Market Signals| Indicator | PUMP | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 51.05 |
| Support Level | $10.26 | $1.20 |
| Resistance Level | $13.25 | $1.68 |
| Average True Range (ATR) | 0.87 | 0.16 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 56.63 | 27.00 |
Price Performance
Historical ComparisonAbout PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.